JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

Home・Listă Acțiuni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Închisă

SectorSănătate

23.55 1.03

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

22.96

Maxim

23.96

Indicatori cheie
By Trading Economics
Venit	10M 17M
Vânzări	30M 130M
EPS	0.13
Marjă de profit	13.432
Angajați	354
EBITDA	11M 22M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+48.82% upside

Dividende
By Dow Jones
Următoarele câștiguri	6 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-294M 2.9B
Deschiderea anterioară	22.52
Închiderea anterioară	23.55

Sentimentul știrilor

By Acuity

55%

45%

292 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

12.42 / 14.93 Suport & Rezistență

Arcutis Biotherapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 mai 2026, 22:17 UTC

Câștiguri

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 mai 2026, 23:47 UTC

Câștiguri

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 mai 2026, 23:45 UTC

Câștiguri

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 mai 2026, 23:45 UTC

Câștiguri

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 mai 2026, 22:44 UTC

Achiziții, Fuziuni, Preluări

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 mai 2026, 22:43 UTC

Achiziții, Fuziuni, Preluări

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 mai 2026, 22:42 UTC

Achiziții, Fuziuni, Preluări

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 mai 2026, 22:42 UTC

Achiziții, Fuziuni, Preluări

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 mai 2026, 22:41 UTC

Achiziții, Fuziuni, Preluări

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 mai 2026, 22:41 UTC

Achiziții, Fuziuni, Preluări

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 mai 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Regis: Shareholders to Own About 51% of Combined Company

4 mai 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Regis: Board Unanimously Endorsed, Supported Deal

4 mai 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Regis: Deal Unanimously Recommended by Vault Board

4 mai 2026, 22:39 UTC

Achiziții, Fuziuni, Preluări

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 mai 2026, 22:38 UTC

Achiziții, Fuziuni, Preluări

Regis Resources to Acquire All Ordinary Shares in Vault

4 mai 2026, 22:38 UTC

Achiziții, Fuziuni, Preluări

Regis Resources, Vault Minerals Agree to Merger of Equals

4 mai 2026, 22:37 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 mai 2026, 22:26 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 mai 2026, 22:02 UTC

Câștiguri

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 mai 2026, 21:52 UTC

Câștiguri

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 mai 2026, 21:50 UTC

Câștiguri

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 mai 2026, 21:50 UTC

Câștiguri

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 mai 2026, 21:49 UTC

Câștiguri

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 mai 2026, 21:44 UTC

Câștiguri

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 mai 2026, 21:44 UTC

Câștiguri

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 mai 2026, 21:43 UTC

Câștiguri

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 mai 2026, 21:41 UTC

Câștiguri

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 mai 2026, 21:40 UTC

Câștiguri

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Comparație

Modificare preț

Arcutis Biotherapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

48.82% sus

Prognoză pe 12 luni

Medie 34.75 USD 48.82%

Maxim 36 USD

Minim 33 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Arcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

12.42 / 14.93Suport & Rezistență

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

292 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.